SEC Filings

S-1
AVEXIS, INC. filed this Form S-1 on 01/15/2016
Entire Document
 

Table of Contents

 


The Offering

Common stock offered by us

               shares

Common stock to be outstanding after this offering

 

             shares

Option to purchase additional shares

 

The underwriters have a 30-day option to purchase a maximum of             additional shares of common stock.

Use of proceeds

 

We estimate that the net proceeds to us from this offering, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us, will be $              million, or $              million if the underwriters exercise in full their option to purchase additional shares, assuming the shares are offered at $             per share, which is the midpoint of the price range set forth on the cover page of this prospectus.

 

We intend to use the net proceeds from this offering, together with our existing cash and cash equivalents, to fund our ongoing Phase 1 clinical trial and future SMA trials for AVXS-101, manufacturing activities to support our ongoing and future trials for AVXS-101, including the establishment of our own manufacturing facility, and for general corporate purposes and working capital. See "Use of Proceeds" on page 75.

Risk factors

 

See "Risk Factors" beginning on page 11 and the other information included in this prospectus for a discussion of factors you should consider carefully before deciding to invest in our common stock.

Proposed NASDAQ Global Market symbol

 

"AVXS"



          The number of shares of our common stock to be outstanding after this offering is based on 6,489,088 shares of our common stock outstanding as of September 30, 2015 and includes 1,268,691 shares of common stock issued pursuant to a restricted stock purchase agreement that are subject to repurchase and, therefore, not considered outstanding for accounting purposes. The number excludes:

    1,147,479 shares of common stock issuable upon the exercise of outstanding stock options as of September 30, 2015, at a weighted-average exercise price of $19.31 per share;

    236,636 shares of common stock issuable upon the exercise of outstanding warrants as of September 30, 2015, at a weighted-average exercise price of $3.55 per share, which warrants are expected to remain outstanding at the consummation of this offering;

    up to a maximum of 307,922 shares of common stock reserved for future issuance under our Amended and Restated 2014 Stock Plan, or the 2014 Plan, as of September 30, 2015; and

7



© AveXis, Inc. All Rights Reserved.